NCT04351165View on ClinicalTrials.gov

BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

February 11, 2021

Study Completion Date

April 30, 2021

Conditions
Solid Tumor
Interventions
DRUG

IMP4297

IMP4297 10mg/capsule; IMP4297 20mg/capsule;

Trial Locations (1)

Unknown

Syneos Health, Sydney

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY